Existing drug class may help patients with skin cancer that resists standard treatments

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup